Enovis stock analysis
Enovis (0I1B) Share Price & Analysis
0I1B Stock Chart & Stats
- Day’s Range
- $27.46 - $28.44
- 52-Week Range
- $16.73 - $32.21
- Previous Close
- $27.99
- Volume
- N/A
- Average Volume (3M)
- 999
- Market Cap
- $1.57B
- Enterprise Value
- $2.37B
- Total Cash (Recent Filing)
- $65.35M
- Total Debt (Recent Filing)
- $1.34B
- Price to Earnings (P/E)
- ―
- Beta
- 1.06
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 1.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue Growth
The sharp acceleration in revenue indicates stronger commercial traction across Enovis’s orthopedic and recovery portfolio. If sustained, expanding sales provide greater operating leverage, support investment in innovation, and strengthen the company’s ability to build scale across hospitals, surgeons, and outpatient channels.
Improving Cash Generation
Improving operating cash flow and a return to positive free cash flow provide tangible support for the business despite accounting losses. Better cash conversion can fund product development, integration work, and debt reduction, while increasing financial flexibility over the next several quarters.
Expanding Surgical Technology Platform
The proposed robotics acquisition could broaden Enovis’s offering from implants and instruments into planning, navigation, assistance, and robotic surgery. That wider ecosystem may deepen relationships with hospitals and ambulatory centers while creating a platform for future procedure-driven growth.
Bears Say
Persistent Net Losses
Deep net losses remain the clearest fundamental weakness and show that revenue growth has not yet translated into GAAP profitability. Continued losses can constrain retained capital, weaken returns on equity, and make the business more dependent on successful operating improvement and cash discipline.
Higher Financial Leverage
Rising leverage reduces financial flexibility while Enovis is still absorbing losses and funding strategic expansion. Additional debt tied to the robotics transaction could increase interest and repayment demands, leaving less capacity to withstand weaker procedures or invest through a slower operating period.
Margin And Demand Pressure
Underlying gross-margin pressure suggests that pricing competition, unfavorable mix, and higher input and distribution costs can offset productivity gains. If these forces persist, they could limit the conversion of strong revenue growth into durable earnings and cash-flow improvement.
Enovis News
0I1B FAQ
What was Enovis’s price range in the past 12 months?
What is Enovis’s market cap?
When is Enovis’s upcoming earnings report date?
How were Enovis’s earnings last quarter?
Is Enovis overvalued?
Does Enovis pay dividends?
What is Enovis’s EPS estimate?
How many shares outstanding does Enovis have?
What happened to Enovis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Enovis?
What is the TipRanks Smart Score and how is it calculated?
Enovis Stock Smart Score
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Damien McDonald
- Employees
- 7,802
- Website
- www.enovis.com
- Address
- 2900 Lake Vista Drive, Lewisville, TX, 75067, US
Enovis (0I1B) Earnings & Revenues
0I1B Company Deck
0I1B Earnings Call
Earnings Call SentimentPositive
The call was broadly constructive. The company delivered 5% organic growth, expanded adjusted margins, increased EPS and free cash flow, raised EBITDA and EPS guidance, and reported momentum from Nebula, ARVIS, Manifuse, and the planned Essential Robotics acquisition. These positives outweighed challenges from market volatility, international pressure, pricing and inflationary costs, softer U.S. hips and knees, and currency headwinds.
View all GB:0I1B earnings summaries0I1B Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 11 | 0 | 1 |












